Chris Gibson, Recursion CEO (Vaughn Ridley/Sportsfile for Web Summit via Getty Images)

Re­cur­sion nabs $239M and an up to $1B part­ner­ship with Bay­er as AI race heats up

Some biotechs strug­gle for cash. Re­cur­sion, late­ly, seems to be swim­ming in it.

To­day, hav­ing al­ready raised over $180 mil­lion in the last two years, the Salt Lake City-based AI drug de­vel­op­er an­nounced a $239 mil­lion Se­ries D. That’s more than any US or Eu­ro­pean biotech has raised in a round this year and more than all but two biotechs raised last year. (Mab­well, a Shang­hai-based an­ti­body de­vel­op­er, raised $278 mil­lion in a Se­ries A in April.)

The round came with an im­por­tant point of val­i­da­tion for Re­cur­sion and a po­ten­tial long-term source of rev­enue: a new part­ner­ship with Bay­er. That deal, cen­tered on fi­brot­ic dis­eases, will pay Re­cur­sion $30 mil­lion up­front for the part­ner­ship, along with $100 mil­lion in mile­stones for each of up to 10 pro­grams the com­pa­nies could pur­sue. So it’s an up to $1 bil­lion deal, even if it’s van­ish­ing­ly un­like­ly to reach that. Leaps by Bay­er, the Ger­man phar­ma’s ven­ture arm, al­so led the Se­ries D, con­tribut­ing a $50 mil­lion eq­ui­ty in­vest­ment.

The in­vest­ment-part­ner­ship rep­re­sents one of the largest rounds, if not the sin­gle largest round, for an ar­ti­fi­cial-in­tel­li­gence fo­cused biotech and ce­ments Re­cur­sion as one of the ma­jor play­ers in a nascent field that has pro­duced many small star­tups but few heavy­weights. It al­so points to where Big Phar­ma and ma­jor VCs may spread their fo­cus as ma­chine learn­ing ap­proach­es ad­vance. The first small com­pa­nies to make head­lines and sign deals used ma­chine learn­ing to screen vast li­braries of mol­e­cules in search of ones that can hit tar­gets that drug com­pa­nies have long tried to hit. More re­cent­ly, though, a cou­ple up­starts have raised sig­nif­i­cant cash and scored promi­nent part­ner­ships us­ing ad­vanced com­pu­ta­tion­al tools to study cells more close­ly and come up with new tar­gets them­selves.

“What Re­cur­sion does is re­al­ly hard so I wouldn’t say there is go­ing to be a del­uge of com­pa­nies,” Zachary Bogue, founder of ear­ly Re­cur­sion backer DCVC, told End­points News. “But this idea of bi­ol­o­gy as a plat­form and us­ing AI as a drug dis­cov­ery is the new fron­tier in biotech.”

Rough­ly, that’s what Re­cur­sion does. In a 100,000 square-foot ware­house in down­town Salt Lake City, ro­bots take petri dish­es of dif­fer­ent cell types and knock out dif­fer­ent genes, tak­ing con­stant pic­tures in the process. Hu­mans can’t eas­i­ly tell the dif­fer­ence be­tween most of those pic­tures, but com­put­ers can, and with enough im­ages and hun­dreds of dif­fer­ent mea­sure­ments on each, they can pick up pat­terns to in­di­cate what can make a cell sick and which genes, when tar­get­ed, can make them healthy.  They can then iden­ti­fy and tweak mol­e­cules or com­pounds that hit those tar­gets.

So far, they’ve used that ap­proach to iden­ti­fy mol­e­cules to bring in­to clin­i­cal de­vel­op­ment for sev­er­al rare neu­ro­log­i­cal con­di­tions and hered­i­tary can­cer syn­drome, pulling com­pounds from Ohio State, Take­da, and co-founder Dean Li’s labs. But the com­pa­ny lists a bevy of pre­clin­i­cal dis­ease ar­eas on its pipeline, and Re­cur­sion CEO Chris Gib­son said that, with the Bay­er deal, they would be­gin to look to part­ner with big com­pa­nies where clin­i­cal de­vel­op­ment is more com­plex, such as in neu­rol­o­gy and on­col­o­gy.

“We’ve been talk­ing about this in­ter­nal­ly as the be­gin­ning of a sec­ond act for the com­pa­ny,” he said in an in­ter­view with End­points.

Oth­er com­pa­nies have scored large amounts of cap­i­tal with sim­i­lar ap­proach­es. Most no­tably, Daphne Koller’s start­up In­sitro has nabbed two $100 mil­lion-plus rounds in a span of 13 months, plus a Gilead col­lab­o­ra­tion on NASH. In Jan­u­ary, star Cana­di­an re­searcher Bren­dan Frey’s Deep Ge­nomics raised $40 mil­lion in­to the clin­ic. Mean­while, the rhetoric from the hand­ful of drug phar­ma ex­ec­u­tives who talk open­ly about ma­chine learn­ing, such as Glax­o­SmithK­line’s Hal Bar­ron, has cen­tered on ap­proach­es that help un­cov­er not just new mol­e­cules but al­so new tar­gets.

Un­der the deal with Bay­er, Re­cur­sion will use their sys­tem to build mod­els for dif­fer­ent fi­brot­ic dis­eases, fol­low­ing guid­ance from Bay­er fi­bro­sis ex­perts at the phar­ma. They will then use Bay­er’s li­brary of small mol­e­cules and their own in­ter­nal abil­i­ty to screen and de­vel­op mol­e­cules to come up with pre­clin­i­cal can­di­dates. Around that point, Gib­son said, they’ll hand things off to Ger­many.

Al­though Leaps by Bay­er de­scribed their $50 mil­lion con­tri­bu­tion to the Se­ries D as “our big bet in terms of dig­i­tal drug dis­cov­ery,” Bay­er it­self has al­so in­vest­ed in the mol­e­cule-screen­ing side of the AI biotech world, as have oth­er ma­jor com­pa­nies. In Jan­u­ary, Bay­er and the UK-based Ex­sci­en­tia signed a dis­cov­ery col­lab­o­ra­tion for up to €240 mil­lion. Ex­sci­en­tia has al­so teamed with Sum­it­o­mo, Sanofi and Cel­gene, the last of which in­clud­ed a $25 mil­lion up­front pay­ment. Atom­wise and In­sil­i­co have al­so signed mul­ti­ple big-name part­ner­ships, al­though they have been large­ly mile­stone-heavy, with lit­tle up­front dis­closed.

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA has vowed not to let politics overrule science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped the FDA and other health agencies under his purview of their rule making ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

UP­DAT­ED: Two wild weeks for Grail end in $8B Il­lu­mi­na buy­out

Grail’s whirlwind two weeks have ended in the wealthy arms of its former founder and benefactors.

Illumina has shelled out $8 billion to reacquire the closely-watched liquid biopsy startup they spun out just 5 years ago and sold off much of its shares just 3 years ago. The deal comes nearly two weeks after the well-heeled startup filed for a potentially massive IPO — one that was disrupted just a week later when Bloomberg reported that Illumina was in talks to buy their former spinout for up to $8 billion.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

Roche vaults to the front of the NL­RP3 clin­i­cal race, pay­ing $448M up­front to bag In­fla­zome

Roche is going all in on NLRP3.

The pharma giant is putting down $448 million (€380 million) upfront to snatch Novartis-backed Inflazome, which makes it a clinical player in the space overnight.

Dublin and Cambridge, UK-based Inflazome is the second NLRP3-focused biotech Roche has acquired in less than two years, and although no numbers were disclosed in the Jecure buyout, this is almost certainly a much larger deal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

President Donald Trump (via AP Images)

Signs of an 'Oc­to­ber Vac­cine Sur­prise' alarm ca­reer sci­en­tists

President Donald Trump, who seems intent on announcing a COVID-19 vaccine before Election Day, could legally authorize a vaccine over the objections of experts, officials at the FDA and even vaccine manufacturers, who have pledged not to release any vaccine unless it’s proved safe and effective.

In podcasts, public forums, social media and medical journals, a growing number of prominent health leaders say they fear that Trump — who has repeatedly signaled his desire for the swift approval of a vaccine and his displeasure with perceived delays at the FDA — will take matters into his own hands, running roughshod over the usual regulatory process.

#ES­MO20: Push­ing in­to front­line, Mer­ck and Bris­tol My­ers duke it out with new slate of GI can­cer da­ta

Having worked in parallel for years to move their respective PD-1 inhibitors up to the first-line treatment of gastrointestinal cancers, Merck and Bristol Myers Squibb finally have the data at ESMO for a showdown.

Comparing KEYNOTE-590 and CheckMate-649, of course, comes with the usual caveats. But a side-by-side look at the overall survival numbers also offer some perspective on a new frontier for the reigning checkpoint rivals, both of whom are claiming to have achieved a first.

Is­raeli biotech rais­es $57M to go where cur­rent BRAF in­hibitors can't, with back­ing from No­var­tis, SR One

For the blockbuster potential of Novartis’ Tafinlar and Pfizer’s Braftovi, all the BRAF inhibitors on the market so far only target V600 mutations — which accounts for roughly 50% of patients.

Israeli biotech Novellus now has $57 million to develop a drug that they say can help the other 50% who have everything else.

The Series C will fund a Phase II trial for PLX-8394, a “paradox breaker” that could block RAF without activating MAPK signaling. In a Phase I trial, a patient with a BRAF fusion saw their tumor go away after taking the drug, allowing Novellus to hit the ground running.

Jonathan Rigby, Immune Regulation group CEO

Im­mune Reg­u­la­tion, tak­ing two clin­i­cal pro­grams to 're­set' the im­mune sys­tem, nets $53M+ Se­ries B

A little under two years after a company rebranding, Immune Regulation is taking an even bigger step toward advancing its goals.

Formerly known as Peptinnovate, the British biotech announced a $53.4 million Series B early Monday morning, helping to further advance two clinical programs in rheumatoid arthritis and asthma. Though those are the two initial indications the company is focusing on, CEO Jonathan Rigby told Endpoints News he hopes the candidates can be applied to a broad swath of autoimmune disorders.

Sebastian Nijman (file photo)

Roche looks to ge­net­ic mod­i­fiers for new drug tar­gets, team­ing up with Dutch biotech in $375M deal

Roche is gambling on a new way of discovering drug targets and, ultimately, promising to infuse more than $375 million into a small biotech if all goes well.

A spinout of the Netherlands Cancer Institute and Oxford University, Scenic Biotech set out to pioneer a field that’s gaining some traction among top VCs in the US: to harness the natural protecting powers of genetic modifiers — specific genes that suppress a disease phenotype.

Anthony Fauci (AP Images)

A press of­fi­cer at An­tho­ny Fau­ci’s NI­AID was un­masked as a hard-right Covid troll. He just re­tired to­day

William B Crews had been a public affairs specialist at the NIH’s National Institute of Allergy and Infectious Diseases.

That ended today when he informed the agency of his decision to retire, after he was identified as the managing editor at RedState, a prominent Trump loyalist website.

Crews’ RedState duties are performed under the alias streiff. While enjoying the benefits of pseudonymity, he disparaged and worked against NIAID with an incendiary level of rhetoric in the midst of a pandemic.